|
2
Votes
vote
Roche's peg-EPO product Mircera infringes Amgen patentsAmgen (Nasdaq: AMGN) today announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court's decision that Roche's peg-EPO product, Mircera, infringes four Amgen patents ('868, '698, '933 and '422) relating to recombinant erythropoietin (EPO) and processes fo... |

